Back

Defence Therapeutics expands radiopharmaceutical program to alpha and beta emitters

Verifying
  • Defence Therapeutics is expanding its radiopharmaceutical development program.
  • The program will include both alpha- and beta-emitting radioisotopes.
  • The company aims to broaden its proprietary Accum technology’s capabilities.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.